Knee Osteoarthritis Musculoskeletal Diseases
Conditions
Interventions
This is a three-arm randomized controlled clinical trial, assessor-blinded. Training group: 42 participants diagnosed with knee osteoarthritis and a body mass index classified as normal weight, overwe
they will only receive guidance to be followed at home for management and self-care of the condition and will be monitored during the intervention period. For both training groups, 2 sessions per week
Sponsors
Universidade São Francisco
Universidade São Francisco
Eligibility
Age
50 Years to 75 Years
Inclusion criteria
Inclusion criteria: Clinical diagnosis of knee osteoarthritis (KOA); age between 50 and 75 years, of both sexes; report of significant knee joint pain for at least 3 months, with a score greater than 40 millimeters assessed using the Visual Analog Scale (VAS); Body Mass Index (BMI) classified as normal weight, overweight, or class I obesity; ability to walk independently; not using assistive walking devices; and absence of neurological impairments. In cases of bilateral involvement, the limb with the greatest pain complaint will be considered.
Exclusion criteria
Exclusion criteria: Active cancer diagnosis; neurological impairments that affect gait; Body Mass Index (BMI) classified as class II or III obesity; uncontrolled systemic arterial hypertension; systemic rheumatic conditions; postoperative status following knee joint replacement or replacement of other joints in the affected limb; and having received injectable treatments within the last 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| An improvement in body balance is expected, assessed using the Four Square Step Test (FSST), a validated instrument for analyzing dynamic balance, coordination, and fall risk. Data will be collected at baseline, midway through the intervention (5 weeks), at the end of the intervention (8 weeks), and at follow-up at 12 and 20 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| An improvement in muscle strength is expected, assessed through hand-held dynamometry and the 30-second Sit-to-Stand (STS) test. Data will be collected at baseline, mid-intervention (5 weeks), at the end of the intervention (8 weeks), and at follow-up at 12 and 20 weeks.;Pain reduction, assessed using the Visual Analogue Scale (VAS), is expected. Data will be collected at baseline, midway through the intervention (5 weeks), at the end of the intervention (8 weeks), and at follow-up at 12 and 20 weeks.;Improvements in knee function and quality of life are expected, as measured by the Knee Injury and Osteoarthritis Outcome Score (KOOS). Data will be collected at baseline, at the end of the intervention (8 weeks), and at follow-up at 12 and 20 weeks.;An improvement in functionality is expected, assessed through the Timed Up and Go (TUG) clinical test. Data will be collected at baseline, mid-intervention (5 weeks), at the end of the intervention (8 weeks), and at follow-up at 12 and 20 weeks.;An improvement in static balance, assessed using the 4-Stage Balance Test, is expected. Data will be collected at baseline, midway through the intervention (5 weeks), at the end of the intervention (8 weeks), and at follow-up at 12 and 20 weeks.;An improvement in the overall perception of change, assessed using the Patient Global Impression of Change (PGIC), is expected. Data will be collected at the end of the intervention (8 weeks). | — |
Countries
BR
Contacts
Public ContactCamila Bianco
Universidade São Francisco
Outcome results
None listed